EOI response rates among response-evaluable patients
| . | ORR, n/N (%) (95% CI) . | CR, n/N (%) (95% CI) . | PR, n/N (%) (95% CI) . |
|---|---|---|---|
| Overall | 84/87 (97) (90-99) | 78/87 (90) (81-95) | 6/87 (7) (3-14) |
| Cohort | |||
| DFCI off trial | 47/47 (100) (92-100) | 44/47 (94) (82-99) | 3/47 (6) (1-18) |
| DFCI trial* | 22/23 (96) (78-100) | 22/23 (96) (78-100) | 0/23 (0) (0-15) |
| WUSTL trial | 15/17 (88) (64-99) | 12/17 (71) (44-90) | 3/17 (18) (4-43) |
| MIPI | |||
| Low | 47/47 (100) (92-100) | 43/47 (91) (80-98) | 4/47 (9) (2-20) |
| Intermediate | 15/16 (94) (70-100) | 15/16 (94) (70-100) | 0/16 (0) (0-21) |
| High | 14/16 (88) (62-98) | 12/16 (75) (48-93) | 2/16 (12) (2-38) |
| Ki67 | |||
| ≤30% | 48/49 (98) (89-100) | 45/49 (92) (80-98) | 3/49 (6) (1-17) |
| >30% | 19/20 (95) (75-100) | 17/20 (85) (62-97) | 2/20 (10) (1-32) |
| Histologic subtype | |||
| Other | 73/75 (97) (91-100) | 69/75 (92) (83-97) | 4/75 (5) (1-13) |
| Blastoid/pleomorphic | 10/11 (91) (59-100) | 9/11 (82) (4-98) | 1/11 (9) (0-41) |
| Starting cytarabine dose | |||
| 3 g/m2 | 28/28 (100) (88-100) | 25/28 (89) (72-98) | 3/28 (11) (2-28) |
| <3 g/m2 | 53/56 (95) (85-99) | 50/56 (89) (78-96) | 3/56 (5) (1-15) |
| Cumulative cytarabine dose† | |||
| ≤24 g/m2 | 52/53 (98) (90-100) | 51/53 (96) (87-100) | 1/53 (2) (0-10) |
| >24 g/m2 | 28/28 (100) (88-100) | 25/28 (89) (72-98) | 3/28 (11) (2-28) |
| . | ORR, n/N (%) (95% CI) . | CR, n/N (%) (95% CI) . | PR, n/N (%) (95% CI) . |
|---|---|---|---|
| Overall | 84/87 (97) (90-99) | 78/87 (90) (81-95) | 6/87 (7) (3-14) |
| Cohort | |||
| DFCI off trial | 47/47 (100) (92-100) | 44/47 (94) (82-99) | 3/47 (6) (1-18) |
| DFCI trial* | 22/23 (96) (78-100) | 22/23 (96) (78-100) | 0/23 (0) (0-15) |
| WUSTL trial | 15/17 (88) (64-99) | 12/17 (71) (44-90) | 3/17 (18) (4-43) |
| MIPI | |||
| Low | 47/47 (100) (92-100) | 43/47 (91) (80-98) | 4/47 (9) (2-20) |
| Intermediate | 15/16 (94) (70-100) | 15/16 (94) (70-100) | 0/16 (0) (0-21) |
| High | 14/16 (88) (62-98) | 12/16 (75) (48-93) | 2/16 (12) (2-38) |
| Ki67 | |||
| ≤30% | 48/49 (98) (89-100) | 45/49 (92) (80-98) | 3/49 (6) (1-17) |
| >30% | 19/20 (95) (75-100) | 17/20 (85) (62-97) | 2/20 (10) (1-32) |
| Histologic subtype | |||
| Other | 73/75 (97) (91-100) | 69/75 (92) (83-97) | 4/75 (5) (1-13) |
| Blastoid/pleomorphic | 10/11 (91) (59-100) | 9/11 (82) (4-98) | 1/11 (9) (0-41) |
| Starting cytarabine dose | |||
| 3 g/m2 | 28/28 (100) (88-100) | 25/28 (89) (72-98) | 3/28 (11) (2-28) |
| <3 g/m2 | 53/56 (95) (85-99) | 50/56 (89) (78-96) | 3/56 (5) (1-15) |
| Cumulative cytarabine dose† | |||
| ≤24 g/m2 | 52/53 (98) (90-100) | 51/53 (96) (87-100) | 1/53 (2) (0-10) |
| >24 g/m2 | 28/28 (100) (88-100) | 25/28 (89) (72-98) | 3/28 (11) (2-28) |